Center-Authored Papers

Filters: Author is Chow, Laura Q M  [Clear All Filters]
Journal Article
Mok TSK, Crino L, Felip E, Salgia R, De Pas T, Tan DSW, Chow LQM.  2017.  The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy.. Cancer treatment reviews. 55:181-189. Abstract
Kim D-W, Mehra R, Tan DSW, Felip E, Chow LQM, Camidge RD, Vansteenkiste J, Sharma S, De Pas T, Riely GJ et al..  2016.  Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.. The Lancet. Oncology. Abstract
Yan J, Liu Q, Moseley JN, Baik CS, Chow LQM, Goulart BH, Zlotnick D, Papanicolau-Sengos A, Gallaher I, Knopp JM et al..  2016.  Adjuvant Radiotherapy for Stages II and III Resected Thymoma: A Single-Institutional Experience.. American journal of clinical oncology. 39(3):223-227. Abstract
Chow LQM, Haddad R, Gupta S, Mahipal A, Mehra R, Tahara M, Berger R, Eder JP, Burtness B, Lee S-H et al..  2016.  Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Abstract
Shaw AT, Kim D-W, Mehra R, Tan DSW, Felip E, Chow LQM, Camidge RD, Vansteenkiste J, Sharma S, De Pas T et al..  2014.  Ceritinib in ALK-rearranged non-small-cell lung cancer.. The New England journal of medicine. 370(13):1189-97. Abstract
Pennock GK, Chow LQM.  2015.  The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment.. The oncologist. Abstract
Santana-Davila R, Bhatia S, Chow LQM.  2016.  Harnessing the Immune System as a Therapeutic Tool in Virus-Associated Cancers.. JAMA oncology. Abstract
Baik CS, Rubin EH, Forde PM, Mehnert JM, Collyar D, Butler MO, Dixon EL, Chow LQM.  2017.  Immuno-oncology Clinical Trial Design: Limitations, Challenges, and Opportunities.. Clinical cancer research : an official journal of the American Association for Cancer Research. 23(17):4992-5002. Abstract
Anagnostou V, Yarchoan M, Hansen AR, Wang H, Verde F, Sharon E, Collyar D, Chow LQM, Forde PM.  2017.  Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity.. Clinical cancer research : an official journal of the American Association for Cancer Research. 23(17):4959-4969. Abstract
Chow LQM, Smith DC, Tan AR, Denlinger CS, Wang D, Shepard DR, Chaudhary A, Lin Y, Gao L.  2016.  Lack of pharmacokinetic drug-drug interaction between ramucirumab and paclitaxel in a phase II study of patients with advanced malignant solid tumors.. Cancer chemotherapy and pharmacology. 78(2):433-41. Abstract
Yearley JH, Gibson C, Yu N, Moon C, Murphy E, Juco J, Lunceford J, Cheng J, Chow LQM, Seiwert TY et al..  2017.  PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer.. Clinical cancer research : an official journal of the American Association for Cancer Research. 23(12):3158-3167. Abstract
Nanda R, Chow LQM, Dees CE, Berger R, Gupta S, Geva R, Pusztai L, Pathiraja K, Aktan G, Cheng JD et al..  2016.  Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 34(21):2460-7. Abstract
Chow LQM, Morishima C, Eaton KD, Baik CS, Goulart BH, Anderson LN, Manjarrez KL, Dietsch GN, Bryan JK, Hershberg RM et al..  2016.  Phase 1b Trial of the Toll-Like Receptor 8 Agonist, Motolimod (VTX-2337), Combined with Cetuximab in Patients with Recurrent or Metastatic SCCHN.. Clinical cancer research : an official journal of the American Association for Cancer Research. Abstract
Leighl NB, Rizvi NA, de Lima LG, Arpornwirat W, Rudin CM, Chiappori AA, Ahn M-J, Chow LQM, Bazhenova L, Dechaphunkul A et al..  2016.  Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non-Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations.. Clinical lung cancer. Abstract
Méndez E, Rodriguez CP, Kao M, Raju SC, Diab A, Harbison RA, Konnick EQ, Mugundu G, Santana-Davila R, Martins R et al..  2018.  A Phase I Clinical Trial of AZD1775 in Combination With Neoadjuvant Weekly Docetaxel and Cisplatin Before Definitive Therapy in Head and Neck Squamous Cell Carcinoma.. Clinical cancer research : an official journal of the American Association for Cancer Research. 24(12):2740-2748. Abstract
Tolcher AW, Sznol M, Hu-Lieskovan S, Papadopoulos KP, Patnaik A, Rasco D, Di Gravio D, Huang B, Gambhire D, Chen Y et al..  2017.  Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors.. Clinical cancer research : an official journal of the American Association for Cancer Research. Abstract
Peters S, Gettinger S, Johnson ML, Jänne PA, Garassino MC, Christoph D, Toh CK, Rizvi NA, Chaft JE, Carcereny Costa E et al..  2017.  Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH).. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. :JCO2016719476. Abstract
Brahmer JR, Tykodi SS, Chow LQM, Hwu W-J, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K et al..  2012.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.. The New England journal of medicine. 366(26):2455-65. Abstract
Plimack ER, Bellmunt J, Gupta S, Berger R, Chow LQM, Juco J, Lunceford J, Saraf S, Perini RF, O'Donnell PH.  2017.  Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study.. The Lancet. Oncology. Abstract
Kalemkerian GP, Akerley W, Bogner P, Borghaei H, Chow LQM, Downey RJ, Gandhi L, Ganti AKP, Govindan R, Grecula JC et al..  2013.  Small cell lung cancer.. Journal of the National Comprehensive Cancer Network : JNCCN. 11(1):78-98. Abstract
Chamberlain MC, Baik CS, Gadi VK, Bhatia S, Chow LQM.  2017.  Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma.. Neuro-oncology. 19(1):i1-i24. Abstract